Dianthus Therapeutics, Inc.
DNTH
Clasificación en acciones
#3912
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Precio por acción
$75.21
Última sincronización: 2026-10-19
Capitalización bursátil
$4.21B
Cambio (1 día)
4.33%
Cambio (1 año)
108.93%
País
US
Comercio Dianthus Therapeutics, Inc. (DNTH)
Categoría
Healthcare
Ratio P/B de Dianthus Therapeutics, Inc. (DNTH)
Ratio P/B al October 2026 TTM: 3.57
Según los informes financieros más recientes y el precio de las acciones de Dianthus Therapeutics, Inc., el ratio P/B actual (TTM) es 3.57. Al final de 2023, el ratio P/B era 0.32.
Historial del ratio P/B de Dianthus Therapeutics, Inc. desde 2016 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
